Loading
A phase 3 trial of Pertuzumab and Trastuzumab in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.
A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial is a phase 3 interventional study registered as NCT02320435 by Hoffmann-La Roche, with 154 participants enrolled, started 2015-02-02 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pertuzumab, Trastuzumab and Other Combination Anti-Cancer Therapies.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Flatiron Health (Roche), Pertuzumab, Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Trastuzumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Pertuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/